GetTopicDetailResponse(id=545e16336e2, topicName=SIrP, introduction=SIrP, content=null, image=null, comments=6, allHits=1011, url=https://h5.medsci.cn/topic?id=16336, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=45672, tagList=[TagDto(tagId=45672, tagName=SIrP)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2030066, encodeId=c500203006677, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, objectTitle=Antib Ther：CD47-SIRPα巨噬細(xì)胞免疫檢查點(diǎn)通路靶點(diǎn)阻斷的臨床應(yīng)用潛力, objectType=article, longId=193963, objectId=1660193963a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1660193963a8, replyNumber=0, likeNumber=85, createdTime=2020-09-18, rootId=0, userName=passed water, userId=a92e2500162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1660193963a8, moduleTitle=Antib Ther：CD47-SIRPα巨噬細(xì)胞免疫檢查點(diǎn)通路靶點(diǎn)阻斷的臨床應(yīng)用潛力, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1660193963a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030064, encodeId=774c2030064f6, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, objectTitle=信達(dá)生物與Alector合作在中國(guó)開(kāi)發(fā)抗腫瘤的SIRP-α單抗, objectType=article, longId=190928, objectId=d3031909289d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3031909289d, replyNumber=0, likeNumber=102, createdTime=2020-12-23, rootId=0, userName=passed water, userId=a92e2500162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3031909289d, moduleTitle=信達(dá)生物與Alector合作在中國(guó)開(kāi)發(fā)抗腫瘤的SIRP-α單抗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d3031909289d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030065, encodeId=7ed32030065aa, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, objectTitle=Blood：研究人員正常和惡性造血干細(xì)胞的SIRPA敲入模型, objectType=article, longId=191228, objectId=a98d19122800, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a98d19122800, replyNumber=0, likeNumber=89, createdTime=2020-06-20, rootId=0, userName=passed water, userId=a92e2500162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a98d19122800, moduleTitle=Blood：研究人員正常和惡性造血干細(xì)胞的SIRPA敲入模型, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a98d19122800)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030063, encodeId=291220300635c, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, objectTitle=Blood：靶向抑制CD47-SIRPα的治療活性需要Fc-FcγR的相互作用, objectType=article, longId=177156, objectId=7f171e715695, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f171e715695, replyNumber=0, likeNumber=103, createdTime=2020-03-08, rootId=0, userName=passed water, userId=a92e2500162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f171e715695, moduleTitle=Blood：靶向抑制CD47-SIRPα的治療活性需要Fc-FcγR的相互作用, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7f171e715695)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2030062, encodeId=b81b20300621c, content=<a href='/topic/show?id=545e16336e2' target=_blank style='color:#2F92EE;'>#SIrP#</a>, objectTitle=OSE Immunotherapeutics的免疫檢查點(diǎn)抑制劑： SIRPα單抗BI 765063獲批在晚期實(shí)體瘤患者中進(jìn)行1期臨床研究, objectType=article, longId=161788, objectId=2b6a161e88d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b6a161e88d5, replyNumber=0, likeNumber=97, createdTime=2019-08-02, rootId=0, userName=passed water, userId=a92e2500162, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b6a161e88d5, moduleTitle=OSE Immunotherapeutics的免疫檢查點(diǎn)抑制劑： SIRPα單抗BI 765063獲批在晚期實(shí)體瘤患者中進(jìn)行1期臨床研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2b6a161e88d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
